Table 2.

The univariate and multivariate analyses of overall survival according to HMMR expression, after adjusting for other potential predictors in TCGA (n = 500).

Characteristics	Univariate analysis		Multivariate analysis
	HR (95% CI)	p-value	HR (95% CI)	p-value
T stage (T1–2 vs. T3–4)	1.230 (0.921–1.642)	0.160
N stage (N0 vs. N1–3)	1.257 (0.960–1.647)	0.097	1.606 (1.141–2.259)	0.007
M stage (M1 vs. M0)	4.794 (1.765–13.016)	0.002	4.037 (1.126–14.476)	0.032
Clinical stage (I–II vs. III–IV)	0.824 (0.594–1.142)	0.245
Age (≤ 60 vs. >60)	1.238 (0.945–1.621)	0.122
Gender (Female vs. Male)	0.754 (0.566–1.004)	0.054	0.794 (0.561–1.124)	0.194
Histologic grade (G1–2 vs. G3–4)	0.942 (0.690–1.287)	0.709
Smoker (No vs. Yes)	1.085 (0.775–1.520)	0.633
Alcohol history (No vs. Yes)	0.967 (0.727–1.288)	0.821
TP53 status (WT vs. Mut)	1.531 (1.119–2.094)	0.008	1.948 (1.343–2.825)	<0.001
PIK3CA status (WT vs. Mut)	0.988 (0.702–1.392)	0.946
Radiation therapy (No vs. Yes)	0.623 (0.459–0.846)	0.002	0.502 (0.355–0.710)	<0.001
Race (White vs. Non–white)	1.477 (0.977–2.231)	0.064	1.055 (0.628–1.775)	0.839
HPV (Negative vs. Positive)	1.335 (0.894–1.995)	0.158
HMMR (Low vs. High)	1.432 (1.094–1.875)	0.009	1.628 (1.169–2.266)	0.004

TCGA, The Cancer Genome Atlas database; HMMR, hyaluronan-mediated motility receptor.